UY34233A - ANTITUMORAL COMBINATION THAT INCLUDES OMBRABULINA AND CETUXIMAB, ASSOCIATED WITH RADIOTHERAPY - Google Patents

ANTITUMORAL COMBINATION THAT INCLUDES OMBRABULINA AND CETUXIMAB, ASSOCIATED WITH RADIOTHERAPY

Info

Publication number
UY34233A
UY34233A UY0001034233A UY34233A UY34233A UY 34233 A UY34233 A UY 34233A UY 0001034233 A UY0001034233 A UY 0001034233A UY 34233 A UY34233 A UY 34233A UY 34233 A UY34233 A UY 34233A
Authority
UY
Uruguay
Prior art keywords
ombrabulina
cetuximab
radiotherapy
antitumoral combination
antitumoral
Prior art date
Application number
UY0001034233A
Other languages
Spanish (es)
Inventor
Carrez Chantal
Clemenson Celine
Deutsch Eric
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY34233A publication Critical patent/UY34233A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

No escanear figura.
UY0001034233A 2011-08-01 2012-08-01 ANTITUMORAL COMBINATION THAT INCLUDES OMBRABULINA AND CETUXIMAB, ASSOCIATED WITH RADIOTHERAPY UY34233A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1157044A FR2978663A1 (en) 2011-08-01 2011-08-01 ANTITUMOR COMBINATION COMPRISING OMBRABULIN AND CETUXIMAB ASSOCIATED WITH RADIOTHERAPY

Publications (1)

Publication Number Publication Date
UY34233A true UY34233A (en) 2013-02-28

Family

ID=46832547

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034233A UY34233A (en) 2011-08-01 2012-08-01 ANTITUMORAL COMBINATION THAT INCLUDES OMBRABULINA AND CETUXIMAB, ASSOCIATED WITH RADIOTHERAPY

Country Status (5)

Country Link
AR (1) AR087393A1 (en)
FR (1) FR2978663A1 (en)
TW (1) TW201315461A (en)
UY (1) UY34233A (en)
WO (1) WO2013018018A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259598A (en) 1979-12-20 1981-03-31 General Electric Company Charge transfer signal processing apparatus transversal filter
BR9909393A (en) 1998-04-03 2000-12-26 Ajinomoto Kk Antitumor agent, use of a stilbene derivative and a platinum coordination compound, and, process for the treatment or improvement of a tumor
US20020183266A1 (en) 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
DE60238408D1 (en) 2001-06-25 2011-01-05 Ajinomoto Kk ANTITUMORAL AGENTS
FR2838437B1 (en) 2002-04-11 2004-06-04 Aventis Pharma Sa PROCESSES FOR THE PREPARATION OF COMBRETASTATINS
FR2895258B1 (en) 2005-12-22 2008-03-21 Aventis Pharma Sa COMBINATION COMPRISING COMBRETASTATIN AND ANTICANCER AGENTS
US20090209496A1 (en) * 2008-02-15 2009-08-20 David Chaplin Methods and compositions for enhancing the efficacy of rtk inhibitors
FR2945210B1 (en) 2009-05-07 2011-07-01 Sanofi Aventis ANTITUMOR COMBINATION COMPRISING AVE8062 AND SORAFENIB

Also Published As

Publication number Publication date
AR087393A1 (en) 2014-03-19
WO2013018018A1 (en) 2013-02-07
FR2978663A1 (en) 2013-02-08
TW201315461A (en) 2013-04-16

Similar Documents

Publication Publication Date Title
UY4151Q (en) VINCHA WITH HEADPHONES
UA117565C2 (en) Novel rig-i ligands and methods for producing them
UY4210Q (en) CHAIR
UY4223Q (en) BANK
UY4281Q (en) PLAYER
UY4153Q (en) DRUMS
UY4152Q (en) DRUMS
CL2012001192S1 (en) Bottle.
UY4237Q (en) STOOL
PH12017500071A1 (en) Therapeutic agent for keratoconjunctive disorder
UY34233A (en) ANTITUMORAL COMBINATION THAT INCLUDES OMBRABULINA AND CETUXIMAB, ASSOCIATED WITH RADIOTHERAPY
UY34232A (en) ANTITUMORAL COMBINATION THAT INCLUDES OMBRABULIN AND CISPLATIN, ASSOCIATED WITH RADIOTHERAPY
TWD160310S (en) Goggles
UY4267Q (en) BOTTLE
UY4262Q (en) BOTTLE
UY4163Q (en) BOTTLE
UA91089U (en) Use of bioglobin-y for correction of hypothyroid states in experiment
AU339704S (en) Sofa
AU339705S (en) Sofa
CA144748S (en) Door stop
CL2012003733S1 (en) Bottle
CL2012003732S1 (en) Bottle
CL2012003734S1 (en) Bottle
CL2012003504S1 (en) Bottle
CL2012003141S1 (en) Bottle

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20140528